Glycolipid in Human Glioma: Detection with Specific Antibodies and Its Application for Diagnosis of Gliomas

  • Osamu Nakamura
  • Masao Iwamori


Gangliosides are acidic glycosphingolipids with sialic acid as the negative charge donor, occuring at the highest concentration in brain tissue. Their content and composition are known to change in association with malignant transformation. In general, malignant gliomas reduce the synthesizing ability of Gg4 Cer-containing molecules and contain a higher concentration of the ganglioside GD3, with the degree of malignancy appearing to correlate with the content of GD3 [1–3].


Sialic Acid Malignant Glioma Human Glioma Glioma Tissue Astrocytoma Grade 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Eto Y, Shinoda S (1982) Gangliosides and neutral glycosphinglipids in human brain tumors: Specificity and their significance. Adv Exp Med Biol 152: 279–280PubMedGoogle Scholar
  2. 2.
    Nakamura O, Ishihara E, Iwamori M, Nagai Y, Matsutani M, Nomura K and Takakura K (1987) Lipid composition of human malignant brain tumors (in Japanese). No To Shinkei (Brain and Nerve) 39: 221–226Google Scholar
  3. 3.
    Traylor TD, Hogan EL (1980) Gangliosides of human cerebral astrocytomas. J Neurochem 34: 126–131PubMedCrossRefGoogle Scholar
  4. 4.
    Bernhard H, Meyer Zum Buschenfelde KH, Dippold WG (1989) Ganglioside GD3 shedding by human malignant melanoma cells. Int J Cancer 44: 155–160PubMedCrossRefGoogle Scholar
  5. 5.
    Ladisch S, Wu Z, Frig S, Ulsh L, Schwartz E, Floutsis G, Wiley F, Lenars C, Seeger R (1987) Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer 39: 73–76PubMedCrossRefGoogle Scholar
  6. 6.
    Dippold W, Knuth A, Meyer Zum Buschenfelde KH (1984) Inhibitation of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res 44: 806–810PubMedGoogle Scholar
  7. 7.
    Hoon DB, Irie RF, Cochran AJ (1988) Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2. Cell Immunol 111: 410–419PubMedCrossRefGoogle Scholar
  8. 8.
    Ladisch S, Gillard B, Wong C, Ulsh L (1983) Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res 43: 3808–3813PubMedGoogle Scholar
  9. 9.
    Seyfried TN, Yu RK (1985) Ganglioside GD3: Structure, cellular distribution and possible function. Mol Cell Biochem 68: 3–10PubMedGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1991

Authors and Affiliations

  • Osamu Nakamura
    • 1
  • Masao Iwamori
    • 2
  1. 1.Department of NeurosurgeryTokyo Metropolitan Komagome HospitalBunkyo-ku, Tokyo, 113Japan
  2. 2.Department of Biochemistry, Faculty of MedicineTokyo UniversityBunkyo-ku, Tokyo, 113Japan

Personalised recommendations